Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine 2024-02-21 09:00
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology 2024-02-20 22:30
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711 2024-02-20 22:00
FDA Grants Orphan Drug Designation to 9MW3011 2024-02-20 22:00
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma 2024-02-20 21:00
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress) 2024-02-20 20:00
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA 2024-02-20 08:22
HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment 2024-02-19 20:18
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S. 2024-02-19 19:30
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis 2024-02-19 09:00
Everest Medicines Announces Termination of Collaboration Agreements with Providence 2024-02-19 08:20
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor 2024-02-18 20:50
Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED. 2024-02-15 17:05
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology 2024-02-15 11:37
YS Biopharma Announces Appointment of New Directors 2024-02-14 20:50
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024 2024-02-14 16:33
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies 2024-02-14 08:07
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. 2024-02-13 03:26
YS Biopharma Announces US$40 Million Private Placement Financing 2024-02-09 19:30
E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical intends to acquire NBL (New Zealand) Limited to help expand the international market 2024-02-08 22:00
1 15 16 17 18 19 377